Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

AGUSTIN MARTINEZ

Allopathic & Osteopathic Physicians General Practice

NPI
1194762427
CMS profile
1109188
Location
HIALEAH, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$199.34

6 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $199.34 6

By paying entity

PY2022 · entire year · sorted by reported total

Paying entityAmountRecords
GlaxoSmithKline, LLC. $145.88 3
Radius Health, Inc. $21.27 1
Novartis Pharmaceuticals Corporation $18.72 1
Lilly USA, LLC $13.47 1

Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

AGUSTIN MARTINEZ

NPI 1194762427 · CMS profile ID 1109188

Allopathic & Osteopathic Physicians / General Practice

HIALEAH, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1194762427?year=2022&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
AGUSTIN MARTINEZ, NPI 1194762427, CMS profile ID 1109188. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1194762427?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). AGUSTIN MARTINEZ, NPI 1194762427, CMS profile ID 1109188. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1194762427?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
AGUSTIN MARTINEZ, NPI 1194762427, CMS profile ID 1109188, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1194762427?year=2022&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

6 matching records · $199.34 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 6 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–6 of 6.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
GlaxoSmithKline, LLC. $8.7512/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944883535 CMS
Novartis Pharmaceuticals Corporation $18.7210/04/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893941801 CMS
Lilly USA, LLC $13.4709/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 917836255 CMS
GlaxoSmithKline, LLC. $17.1406/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944883539 CMS
Radius Health, Inc. $21.2704/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 954935627 CMS
GlaxoSmithKline, LLC. $119.9903/22/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944883537 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $225.20 12
PY2020 $60.00 3
PY2021 $141.84 8
PY2022 $199.34 6
PY2023 $168.87 8
PY2024 $107.88 5
PY2025 $35.74 2

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $156,857.18 33
PY2024 Principal investigator $300,775.87 106
PY2023 Principal investigator $241,925.60 34
PY2022 Principal investigator $40,769.00 10

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

106 records in PY2024

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Bausch Health US, LLC $3,190.58 12/23/2024 Non-covered Recipient Entity
Pharmaseek LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151680739
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $7,406.00 12/19/2024 Non-covered Recipient Entity
WCG CLINICAL INC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1144237524
Principal investigator 1 Bausch Health US, LLC $428.59 12/11/2024 Non-covered Recipient Entity
Pharmaseek LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151680730
Principal investigator 1 Bausch Health US, LLC $2,452.47 12/04/2024 Non-covered Recipient Entity
Pharmaseek LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151680704
Principal investigator 1 Bausch Health US, LLC $3,679.93 11/27/2024 Non-covered Recipient Entity
Pharmaseek LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151680709
Principal investigator 1 GlaxoSmithKline, LLC. $1,200.00 11/20/2024 Non-covered Recipient Entity
PHARMASEEK LLC
A RANDOMISED, DOUBLE-BLIND, PARALLEL GROUP PHASE III STUDY TO ASSESS T No dispute reported 06/30/2026 1127544389
Principal investigator 1 GlaxoSmithKline, LLC. $1,800.00 11/15/2024 Non-covered Recipient Entity
PHARMASEEK LLC
A TWO-PART, RANDOMIZED, PLACEBO CONTROLLED, DOUBLE BLIND, MULTICENTER, No dispute reported 06/30/2026 1127544385
Principal investigator 1 Bausch Health US, LLC $7,363.34 11/04/2024 Non-covered Recipient Entity
Pharmaseek LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151680735
Principal investigator 1 Bausch Health US, LLC $5,521.03 10/29/2024 Non-covered Recipient Entity
Pharmaseek LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151680713
Principal investigator 1 GlaxoSmithKline, LLC. $67.50 10/17/2024 Non-covered Recipient Entity
PHARMASEEK LLC
A RANDOMISED, DOUBLE-BLIND, PARALLEL GROUP PHASE III STUDY TO ASSESS T No dispute reported 06/30/2026 1127516016
Principal investigator 1 GlaxoSmithKline, LLC. $3,645.00 10/17/2024 Non-covered Recipient Entity
PHARMASEEK LLC
A RANDOMISED, DOUBLE-BLIND, PARALLEL GROUP PHASE III STUDY TO ASSESS T No dispute reported 06/30/2026 1127516020
Principal investigator 1 GlaxoSmithKline, LLC. $567.00 10/17/2024 Non-covered Recipient Entity
PHARMASEEK LLC
A RANDOMISED, DOUBLE-BLIND, PARALLEL GROUP PHASE III STUDY TO ASSESS T No dispute reported 06/30/2026 1127516022
Principal investigator 1 GlaxoSmithKline, LLC. $2,160.00 10/17/2024 Non-covered Recipient Entity
PHARMASEEK LLC
A RANDOMISED, DOUBLE-BLIND, PARALLEL GROUP PHASE III STUDY TO ASSESS T No dispute reported 06/30/2026 1127516026
Principal investigator 1 GlaxoSmithKline, LLC. $67.50 10/17/2024 Non-covered Recipient Entity
PHARMASEEK LLC
A RANDOMISED, DOUBLE-BLIND, PARALLEL GROUP PHASE III STUDY TO ASSESS T No dispute reported 06/30/2026 1127516028
Principal investigator 1 GlaxoSmithKline, LLC. $135.00 10/17/2024 Non-covered Recipient Entity
PHARMASEEK LLC
A RANDOMISED, DOUBLE-BLIND, PARALLEL GROUP PHASE III STUDY TO ASSESS T No dispute reported 06/30/2026 1127527504
Principal investigator 1 GlaxoSmithKline, LLC. $945.00 10/17/2024 Non-covered Recipient Entity
PHARMASEEK LLC
A RANDOMISED, DOUBLE-BLIND, PARALLEL GROUP PHASE III STUDY TO ASSESS T No dispute reported 06/30/2026 1127544397
Principal investigator 1 Bausch Health US, LLC $9,371.59 10/09/2024 Non-covered Recipient Entity
Pharmaseek LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151680748
Principal investigator 1 Bausch Health US, LLC $3,679.93 09/20/2024 Non-covered Recipient Entity
Pharmaseek LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151680686
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $5,446.00 09/12/2024 Non-covered Recipient Entity
WCG CLINICAL INC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1144237464
Principal investigator 1 Bausch Health US, LLC $10,304.10 08/29/2024 Non-covered Recipient Entity
Pharmaseek LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151680695
Principal investigator 1 GlaxoSmithKline, LLC. $1,154.25 08/27/2024 Non-covered Recipient Entity
PHARMASEEK LLC
A RANDOMISED, DOUBLE-BLIND, PARALLEL GROUP PHASE III STUDY TO ASSESS T No dispute reported 06/30/2026 1127544391
Principal investigator 1 GlaxoSmithKline, LLC. $2,700.00 08/23/2024 Non-covered Recipient Entity
PHARMASEEK LLC
A RANDOMISED, DOUBLE-BLIND, PARALLEL GROUP PHASE III STUDY TO ASSESS T No dispute reported 06/30/2026 1127516024
Principal investigator 1 Bausch Health US, LLC $29,416.34 08/20/2024 Non-covered Recipient Entity
Pharmaseek LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151680700
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $4,970.00 08/15/2024 Non-covered Recipient Entity
WCG CLINICAL INC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1144237458
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $409.20 07/25/2024 Non-covered Recipient Entity
WCG CLINICAL INC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1144237544
Principal investigator 1 Bausch Health US, LLC $428.59 07/19/2024 Non-covered Recipient Entity
Pharmaseek LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151680691
Principal investigator 1 GlaxoSmithKline, LLC. $158.40 07/18/2024 Non-covered Recipient Entity
PHARMASEEK LLC
A TWO-PART, RANDOMIZED, PLACEBO CONTROLLED, DOUBLE BLIND, MULTICENTER, No dispute reported 06/30/2026 1127516018
Principal investigator 1 GlaxoSmithKline, LLC. $5,814.85 07/18/2024 Non-covered Recipient Entity
PHARMASEEK LLC
A RANDOMISED, DOUBLE-BLIND, PARALLEL GROUP PHASE III STUDY TO ASSESS T No dispute reported 06/30/2026 1127527496
Principal investigator 1 GlaxoSmithKline, LLC. $153.12 07/18/2024 Non-covered Recipient Entity
PHARMASEEK LLC
A TWO-PART, RANDOMIZED, PLACEBO CONTROLLED, DOUBLE BLIND, MULTICENTER, No dispute reported 06/30/2026 1127527498
Principal investigator 1 GlaxoSmithKline, LLC. $129.36 07/18/2024 Non-covered Recipient Entity
PHARMASEEK LLC
A TWO-PART, RANDOMIZED, PLACEBO CONTROLLED, DOUBLE BLIND, MULTICENTER, No dispute reported 06/30/2026 1127544405
Principal investigator 1 GlaxoSmithKline, LLC. $85.80 07/18/2024 Non-covered Recipient Entity
PHARMASEEK LLC
A TWO-PART, RANDOMIZED, PLACEBO CONTROLLED, DOUBLE BLIND, MULTICENTER, No dispute reported 06/30/2026 1127544407
Principal investigator 1 Bausch Health US, LLC $86,287.21 07/10/2024 Non-covered Recipient Entity
Pharmaseek LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151680657
Principal investigator 1 GlaxoSmithKline, LLC. $3,639.74 06/25/2024 Non-covered Recipient Entity
PHARMASEEK LLC
A RANDOMISED, DOUBLE-BLIND, PARALLEL GROUP PHASE III STUDY TO ASSESS T No dispute reported 06/30/2026 1127516030
Principal investigator 1 Bausch Health US, LLC $428.59 06/13/2024 Non-covered Recipient Entity
Pharmaseek LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151680360
Principal investigator 1 Bausch Health US, LLC $1,656.05 06/13/2024 Non-covered Recipient Entity
Pharmaseek LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151680457
Principal investigator 1 Bausch Health US, LLC $1,595.29 06/13/2024 Non-covered Recipient Entity
Pharmaseek LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151680465
Principal investigator 1 Bausch Health US, LLC $428.59 06/13/2024 Non-covered Recipient Entity
Pharmaseek LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151680474
Principal investigator 1 Bausch Health US, LLC $1,662.12 06/13/2024 Non-covered Recipient Entity
Pharmaseek LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151680479
Principal investigator 1 Bausch Health US, LLC $428.59 06/13/2024 Non-covered Recipient Entity
Pharmaseek LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151680492
Principal investigator 1 Bausch Health US, LLC $1,595.29 06/13/2024 Non-covered Recipient Entity
Pharmaseek LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151680505
Principal investigator 1 Bausch Health US, LLC $1,649.97 06/13/2024 Non-covered Recipient Entity
Pharmaseek LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151680522
Principal investigator 1 Bausch Health US, LLC $428.59 06/13/2024 Non-covered Recipient Entity
Pharmaseek LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151680596
Principal investigator 1 Bausch Health US, LLC $1,656.05 06/13/2024 Non-covered Recipient Entity
Pharmaseek LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151680622
Principal investigator 1 Bausch Health US, LLC $1,394.82 06/13/2024 Non-covered Recipient Entity
Pharmaseek LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151680626
Principal investigator 1 Bausch Health US, LLC $1,595.29 06/13/2024 Non-covered Recipient Entity
Pharmaseek LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151680631
Principal investigator 1 Bausch Health US, LLC $1,656.05 06/05/2024 Non-covered Recipient Entity
Pharmaseek LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151680368
Principal investigator 1 Bausch Health US, LLC $428.59 06/05/2024 Non-covered Recipient Entity
Pharmaseek LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151680452
Principal investigator 1 Bausch Health US, LLC $1,595.29 06/05/2024 Non-covered Recipient Entity
Pharmaseek LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151680535
Principal investigator 1 Bausch Health US, LLC $750.00 06/05/2024 Non-covered Recipient Entity
Pharmaseek LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151680587
Principal investigator 1 Bausch Health US, LLC $1,595.29 06/05/2024 Non-covered Recipient Entity
Pharmaseek LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151680609
Principal investigator 1 GlaxoSmithKline, LLC. $1,350.00 05/29/2024 Non-covered Recipient Entity
PHARMASEEK LLC
A RANDOMISED, DOUBLE-BLIND, PARALLEL GROUP PHASE III STUDY TO ASSESS T No dispute reported 06/30/2026 1127544401
Principal investigator 1 GlaxoSmithKline, LLC. $2,128.95 05/21/2024 Non-covered Recipient Entity
PHARMASEEK LLC
A RANDOMISED, DOUBLE-BLIND, PARALLEL GROUP PHASE III STUDY TO ASSESS T No dispute reported 06/30/2026 1127544399
Principal investigator 1 Bausch Health US, LLC $74.25 05/16/2024 Non-covered Recipient Entity
Pharmaseek LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151680364
Principal investigator 1 Bausch Health US, LLC $74.25 05/16/2024 Non-covered Recipient Entity
Pharmaseek LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151680373
Principal investigator 1 Bausch Health US, LLC $168.75 05/16/2024 Non-covered Recipient Entity
Pharmaseek LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151680382
Principal investigator 1 Bausch Health US, LLC $74.25 05/16/2024 Non-covered Recipient Entity
Pharmaseek LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151680386
Principal investigator 1 Bausch Health US, LLC $750.00 05/16/2024 Non-covered Recipient Entity
Pharmaseek LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151680400
Principal investigator 1 Bausch Health US, LLC $74.25 05/16/2024 Non-covered Recipient Entity
Pharmaseek LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151680404
Principal investigator 1 Bausch Health US, LLC $74.25 05/16/2024 Non-covered Recipient Entity
Pharmaseek LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151680408
Principal investigator 1 Bausch Health US, LLC $74.25 05/16/2024 Non-covered Recipient Entity
Pharmaseek LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151680439
Principal investigator 1 Bausch Health US, LLC $168.75 05/16/2024 Non-covered Recipient Entity
Pharmaseek LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151680470
Principal investigator 1 Bausch Health US, LLC $74.25 05/16/2024 Non-covered Recipient Entity
Pharmaseek LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151680500
Principal investigator 1 Bausch Health US, LLC $74.25 05/16/2024 Non-covered Recipient Entity
Pharmaseek LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151680509
Principal investigator 1 Bausch Health US, LLC $168.75 05/16/2024 Non-covered Recipient Entity
Pharmaseek LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151680526
Principal investigator 1 Bausch Health US, LLC $168.75 05/16/2024 Non-covered Recipient Entity
Pharmaseek LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151680539
Principal investigator 1 Bausch Health US, LLC $168.75 05/16/2024 Non-covered Recipient Entity
Pharmaseek LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151680548
Principal investigator 1 Bausch Health US, LLC $750.00 05/16/2024 Non-covered Recipient Entity
Pharmaseek LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151680552
Principal investigator 1 Bausch Health US, LLC $168.75 05/16/2024 Non-covered Recipient Entity
Pharmaseek LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151680565
Principal investigator 1 Bausch Health US, LLC $168.75 05/16/2024 Non-covered Recipient Entity
Pharmaseek LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151680583
Principal investigator 1 Bausch Health US, LLC $74.25 05/16/2024 Non-covered Recipient Entity
Pharmaseek LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151680591
Principal investigator 1 Bausch Health US, LLC $74.25 05/16/2024 Non-covered Recipient Entity
Pharmaseek LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151680600
Principal investigator 1 Bausch Health US, LLC $74.25 05/16/2024 Non-covered Recipient Entity
Pharmaseek LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151680617
Principal investigator 1 Bausch Health US, LLC $74.25 05/16/2024 Non-covered Recipient Entity
Pharmaseek LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151680644
Principal investigator 1 Bausch Health US, LLC $74.25 05/16/2024 Non-covered Recipient Entity
Pharmaseek LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151680648
Principal investigator 1 GlaxoSmithKline, LLC. $4,563.14 04/24/2024 Non-covered Recipient Entity
PHARMASEEK LLC
A RANDOMISED, DOUBLE-BLIND, PARALLEL GROUP PHASE III STUDY TO ASSESS T No dispute reported 06/30/2026 1127527502
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $12,500.00 04/18/2024 Non-covered Recipient Entity
WCG CLINICAL INC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1144237474
Principal investigator 1 Bausch Health US, LLC $1,242.95 04/02/2024 Non-covered Recipient Entity
Pharmaseek LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151680413
Principal investigator 1 Bausch Health US, LLC $1,656.05 04/02/2024 Non-covered Recipient Entity
Pharmaseek LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151680421
Principal investigator 1 Bausch Health US, LLC $428.59 04/02/2024 Non-covered Recipient Entity
Pharmaseek LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151680426
Principal investigator 1 Bausch Health US, LLC $1,656.05 04/02/2024 Non-covered Recipient Entity
Pharmaseek LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151680444
Principal investigator 1 Bausch Health US, LLC $428.59 04/02/2024 Non-covered Recipient Entity
Pharmaseek LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151680483
Principal investigator 1 Bausch Health US, LLC $1,656.05 04/02/2024 Non-covered Recipient Entity
Pharmaseek LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151680496
Principal investigator 1 Bausch Health US, LLC $1,595.29 04/02/2024 Non-covered Recipient Entity
Pharmaseek LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151680543
Principal investigator 1 Bausch Health US, LLC $1,595.29 04/02/2024 Non-covered Recipient Entity
Pharmaseek LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151680604
Principal investigator 1 Bausch Health US, LLC $1,595.29 04/02/2024 Non-covered Recipient Entity
Pharmaseek LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151680635
Principal investigator 1 Bausch Health US, LLC $1,242.95 04/02/2024 Non-covered Recipient Entity
Pharmaseek LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151680640
Principal investigator 1 Bausch Health US, LLC $1,656.05 03/15/2024 Non-covered Recipient Entity
Pharmaseek LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151680761
Principal investigator 1 Bausch Health US, LLC $1,595.29 03/15/2024 Non-covered Recipient Entity
Pharmaseek LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151680782
Principal investigator 1 Bausch Health US, LLC $1,242.95 03/15/2024 Non-covered Recipient Entity
Pharmaseek LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151680795
Principal investigator 1 Bausch Health US, LLC $428.59 03/15/2024 Non-covered Recipient Entity
Pharmaseek LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151680799
Principal investigator 1 Bausch Health US, LLC $1,242.95 03/15/2024 Non-covered Recipient Entity
Pharmaseek LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151680813
Principal investigator 1 Bausch Health US, LLC $428.59 03/15/2024 Non-covered Recipient Entity
Pharmaseek LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151680826
Principal investigator 1 Bausch Health US, LLC $1,722.87 03/15/2024 Non-covered Recipient Entity
Pharmaseek LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151680831
Principal investigator 1 Bausch Health US, LLC $1,595.29 03/15/2024 Non-covered Recipient Entity
Pharmaseek LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151680844
Principal investigator 1 GlaxoSmithKline, LLC. $3,961.64 03/11/2024 Non-covered Recipient Entity
PHARMASEEK LLC
A RANDOMISED, DOUBLE-BLIND, PARALLEL GROUP PHASE III STUDY TO ASSESS T No dispute reported 06/30/2026 1127544393
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $409.20 03/08/2024 Non-covered Recipient Entity
WCG CLINICAL INC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1144237542
Principal investigator 1 GlaxoSmithKline, LLC. $3,305.54 03/07/2024 Non-covered Recipient Entity
PHARMASEEK LLC
A TWO-PART, RANDOMIZED, PLACEBO CONTROLLED, DOUBLE BLIND, MULTICENTER, No dispute reported 06/30/2026 1127544387
Principal investigator 1 Bausch Health US, LLC $1,722.87 02/12/2024 Non-covered Recipient Entity
Pharmaseek LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151680752
Principal investigator 1 Bausch Health US, LLC $2,394.77 02/12/2024 Non-covered Recipient Entity
Pharmaseek LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151680774
Principal investigator 1 Bausch Health US, LLC $1,656.05 02/12/2024 Non-covered Recipient Entity
Pharmaseek LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151680817
Principal investigator 1 Bausch Health US, LLC $1,656.05 02/12/2024 Non-covered Recipient Entity
Pharmaseek LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151680840
Principal investigator 1 GlaxoSmithKline, LLC. $2,119.89 02/05/2024 Non-covered Recipient Entity
PHARMASEEK LLC
A TWO-PART, RANDOMIZED, PLACEBO CONTROLLED, DOUBLE BLIND, MULTICENTER, No dispute reported 06/30/2026 1127544403
Principal investigator 1 GlaxoSmithKline, LLC. $5,236.45 02/01/2024 Non-covered Recipient Entity
PHARMASEEK LLC
A RANDOMISED, DOUBLE-BLIND, PARALLEL GROUP PHASE III STUDY TO ASSESS T No dispute reported 06/30/2026 1127544395
Principal investigator 1 Bausch Health US, LLC $1,595.29 01/29/2024 Non-covered Recipient Entity
Pharmaseek LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151680756
Principal investigator 1 Bausch Health US, LLC $1,595.29 01/29/2024 Non-covered Recipient Entity
Pharmaseek LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151680835
Principal investigator 1 GlaxoSmithKline, LLC. $2,602.68 01/12/2024 Non-covered Recipient Entity
PHARMASEEK LLC
A TWO-PART, RANDOMIZED, PLACEBO CONTROLLED, DOUBLE BLIND, MULTICENTER, No dispute reported 06/30/2026 1127527500